{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:22:15Z","timestamp":1779196935344,"version":"3.51.4"},"reference-count":62,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH Medical Research Scholars Program","award":["DDCF Grant #2014194"],"award-info":[{"award-number":["DDCF Grant #2014194"]}]},{"name":"U.S. Department of Health and Human Services > National Institutes of Health > National Cancer Institute","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["ZIA BC 010944"],"award-info":[{"award-number":["ZIA BC 010944"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CRADA with ImmunityBio","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,11,3]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>While radiation and chemotherapy are primarily purposed for their cytotoxic effects, a growing body of preclinical and clinical evidence demonstrates an immunogenic potential for these standard therapies. Accordingly, we sought to characterize the immunogenic potential of radiation and cisplatin in human tumor models of HPV-associated malignancies. These studies may inform rational combination immuno-oncology (IO) strategies to be employed in the clinic on the backbone of standard of care, and in so doing exploit the immunogenic potential of standard of care to improve durable responses in HPV-associated malignancies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retroviral transduction with HPV16 E7 established a novel HPV-associated sinonasal squamous cell carcinoma (SNSCC) cell line. Three established HPV16-positive cell lines were also studied (cervical carcinoma and head and neck squamous cell carcinoma). Following determination of sensitivities to standard therapies using MTT assays, flow cytometry was used to characterize induction of immunogenic cell stress following sublethal exposure to radiation or cisplatin, and the functional consequence of this induction was determined using impedance-based real time cell analysis cytotoxicity assays employing HPV16 E7-specific cytotoxic lymphocytes (CTLs) with or without N803 (IL-15\/IL-15-R\u03b1 superagonist) or exogenous death receptor ligands. In vitro observations were translated using an in vivo xenograft NSG mouse model of human cervical carcinoma evaluating cisplatin in combination with CTL adoptive cell transfer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We showed that subpopulations surviving clinically relevant doses of radiation or cisplatin therapy were more susceptible to CTL-mediated lysis in four of four tumor models of HPV-associated malignancies, serving as a model for HPV therapeutic vaccine or T-cell receptor adoptive cell transfer. This increased killing was further amplified by IL-15 agonism employing N803. We further characterized that radiation or cisplatin induced immunogenic cell stress in three of three cell lines, and consequently demonstrated that upregulated surface expression of Fas and TRAIL-R2 death receptors at least in part mediated enhanced CTL-mediated lysis. In vivo, cisplatin-induced immunogenic cell stress synergistically potentiated CTL-mediated tumor control in a human model of HPV-associated malignancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Standard of care radiation or cisplatin therapy induced immunogenic cell stress in preclinical models of HPV-associated malignancies, presenting an opportunity poised for exploitation by employing IO strategies in combination with standard of care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005752","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:40:49Z","timestamp":1671788449000},"page":"e005752","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04369937","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03830866","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04221945","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04369937","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04287868","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-7809","authenticated-orcid":false,"given":"Joshua T","family":"Kowalczyk","sequence":"first","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-5647","authenticated-orcid":false,"given":"Kellsye P","family":"Fabian","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle R","family":"Padget","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana C","family":"Lopez","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin TK","family":"Hoke","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-5804","authenticated-orcid":false,"given":"Clint T","family":"Allen","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Hermsen","sequence":"additional","affiliation":[{"name":"Department Head and Neck Cancer, Centro de Investigaci\u00f3n Biom\u00e9dica en Red, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2902-4407","authenticated-orcid":false,"suffix":"Jr","given":"Nyall R","family":"London,","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"},{"name":"Sinonasal and Skull Base Tumor Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5282-3154","authenticated-orcid":false,"given":"James W","family":"Hodge","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"2025100311365916000_10.12.e005752.1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30716"},{"key":"2025100311365916000_10.12.e005752.2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025100311365916000_10.12.e005752.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.1937"},{"key":"2025100311365916000_10.12.e005752.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32470-X"},{"key":"2025100311365916000_10.12.e005752.5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/EDBK_351336","article-title":"Introducing checkpoint inhibitors into the curative setting of head and neck cancers: lessons learned, future considerations","volume":"42","author":"Nenclares","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100311365916000_10.12.e005752.6","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-002492"},{"key":"2025100311365916000_10.12.e005752.7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40136-022-00404-7","article-title":"Human papillomavirus-related carcinomas of the sinonasal tract","volume":"10","author":"Lopez","year":"2022","journal-title":"Curr Otorhinolaryngol Rep"},{"key":"2025100311365916000_10.12.e005752.8","doi-asserted-by":"crossref","first-page":"E388","DOI":"10.1002\/lary.28315","article-title":"Margins in sinonasal squamous cell carcinoma: predictors, outcomes, and the endoscopic approach","volume":"130","author":"Torabi","year":"2020","journal-title":"Laryngoscope"},{"key":"2025100311365916000_10.12.e005752.9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112835","article-title":"Sinonasal squamous cell carcinoma, a narrative reappraisal of the current evidence","volume":"13","author":"Ferrari","year":"2021","journal-title":"Cancers"},{"key":"2025100311365916000_10.12.e005752.10","doi-asserted-by":"crossref","first-page":"573497","DOI":"10.3389\/fcell.2021.573497","article-title":"Integrated analysis of immune infiltration features for cervical carcinoma and their associated immunotherapeutic responses","volume":"9","author":"Kang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2025100311365916000_10.12.e005752.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2140"},{"key":"2025100311365916000_10.12.e005752.12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7470"},{"key":"2025100311365916000_10.12.e005752.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-823757"},{"key":"2025100311365916000_10.12.e005752.14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/14712598.2020.1738379","article-title":"Rationale for IL-15 superagonists in cancer immunotherapy","volume":"20","author":"Knudson","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2025100311365916000_10.12.e005752.15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0009"},{"key":"2025100311365916000_10.12.e005752.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0945"},{"key":"2025100311365916000_10.12.e005752.17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100066"},{"key":"2025100311365916000_10.12.e005752.18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29112"},{"key":"2025100311365916000_10.12.e005752.19","doi-asserted-by":"crossref","DOI":"10.1038\/srep04925","article-title":"Establishment and genetic characterization of six unique tumor cell lines as preclinical models for sinonasal squamous cell carcinoma","volume":"4","author":"Garc\u00eda-Incl\u00e1n","year":"2014","journal-title":"Sci Rep"},{"key":"2025100311365916000_10.12.e005752.20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002128"},{"key":"2025100311365916000_10.12.e005752.21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99488","article-title":"Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model","volume":"3","author":"Jin","year":"2018","journal-title":"JCI Insight"},{"key":"2025100311365916000_10.12.e005752.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000412"},{"key":"2025100311365916000_10.12.e005752.23","doi-asserted-by":"crossref","first-page":"1975-1988","DOI":"10.1007\/s00262-021-03134-9","article-title":"Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer","volume":"71","author":"Salomon","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2025100311365916000_10.12.e005752.24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s42003-020-01598-6","article-title":"Optimal combination treatment regimens of vaccine and radiotherapy augment tumor-bearing host immunity","volume":"4","author":"Zhang","year":"2021","journal-title":"Commun Biol"},{"key":"2025100311365916000_10.12.e005752.25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300149"},{"key":"2025100311365916000_10.12.e005752.26","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1099\/0022-1317-80-7-1725","article-title":"Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSKi, SiHa and HeLa cervical carcinoma cell lines","volume":"80 (Pt 7)","author":"Meissner","year":"1999","journal-title":"J Gen Virol"},{"key":"2025100311365916000_10.12.e005752.27","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin","year":"1996","journal-title":"Cancer Res"},{"key":"2025100311365916000_10.12.e005752.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02082.x"},{"key":"2025100311365916000_10.12.e005752.29","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2725"},{"key":"2025100311365916000_10.12.e005752.30","doi-asserted-by":"crossref","unstructured":"Wolfson B , Hodge JW . Next Generation Therapeutic Strateg\u2010Es: Evolving cancer immunotherapy through agents that Engage, Expand and Enable the anti\u2010tumor immune response. Immunomedicine 2021;1.doi:10.1002\/imed.1020","DOI":"10.1002\/imed.1020"},{"key":"2025100311365916000_10.12.e005752.31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"2025100311365916000_10.12.e005752.32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100311365916000_10.12.e005752.33","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.2001.0405"},{"key":"2025100311365916000_10.12.e005752.34","doi-asserted-by":"crossref","first-page":"23498","DOI":"10.18632\/oncotarget.8274","article-title":"Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin","volume":"7","author":"Kwilas","year":"2016","journal-title":"Oncotarget"},{"key":"2025100311365916000_10.12.e005752.35","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0445-4"},{"key":"2025100311365916000_10.12.e005752.36","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.02.006"},{"key":"2025100311365916000_10.12.e005752.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(03)00707-4"},{"key":"2025100311365916000_10.12.e005752.38","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01666-1"},{"key":"2025100311365916000_10.12.e005752.39","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1038\/s41388-018-0581-9","article-title":"Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles","volume":"38","author":"Grabosch","year":"2019","journal-title":"Oncogene"},{"key":"2025100311365916000_10.12.e005752.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019"},{"key":"2025100311365916000_10.12.e005752.41","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292"},{"key":"2025100311365916000_10.12.e005752.42","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0551-y"},{"key":"2025100311365916000_10.12.e005752.43","doi-asserted-by":"publisher","DOI":"10.1038\/nm1523"},{"key":"2025100311365916000_10.12.e005752.44","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1719"},{"key":"2025100311365916000_10.12.e005752.45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494"},{"key":"2025100311365916000_10.12.e005752.46","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1202"},{"key":"2025100311365916000_10.12.e005752.47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2062"},{"key":"2025100311365916000_10.12.e005752.48","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0577"},{"key":"2025100311365916000_10.12.e005752.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8"},{"key":"2025100311365916000_10.12.e005752.50","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025100311365916000_10.12.e005752.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"2025100311365916000_10.12.e005752.52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005036"},{"key":"2025100311365916000_10.12.e005752.53","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/14737140.2022.2069097","article-title":"What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?","volume":"22","author":"Bilusic","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025100311365916000_10.12.e005752.54","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0638"},{"key":"2025100311365916000_10.12.e005752.55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001691"},{"key":"2025100311365916000_10.12.e005752.56","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/21645515.2017.1364322","article-title":"Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations","volume":"13","author":"Gatti-Mays","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2025100311365916000_10.12.e005752.57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijrobp.2016.02.022","article-title":"Tumor cells surviving exposure to proton or photon radiation share a common immunogenic modulation signature, rendering them more sensitive to T cell-mediated killing","volume":"95","author":"Gameiro","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100311365916000_10.12.e005752.58","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","article-title":"Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?","volume":"13","author":"Bernstein","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100311365916000_10.12.e005752.59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/ITT.S273327","article-title":"Therapeutic vaccines for HPV-associated malignancies","volume":"9","author":"Smalley Rumfield","year":"2020","journal-title":"Immunotargets Ther"},{"key":"2025100311365916000_10.12.e005752.60","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050509","article-title":"Stay on target: Reengaging cancer vaccines in combination immunotherapy","volume":"9","author":"Wolfson","year":"2021","journal-title":"Vaccines"},{"key":"2025100311365916000_10.12.e005752.61","first-page":"2501-2501","article-title":"Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies (abstr; 2021 ASCO annual meeting I, virtual)","volume":"39","author":"Strauss","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100311365916000_10.12.e005752.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.09.028"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:37:14Z","timestamp":1759516634000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":62,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,23]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/jitc-2022-005752"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005752","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}